Vitality Watch

Dossier rss expert media 04-jul-2026
Content from credentialed experts outside peer review — podcasts, blogs, talks

Metformin and cancer: active surveillance needed

Key claim: Attia argues that metformin has failed in prostate cancer and many other cancers, and that rare exceptions require precision and active surveillance rather than blanket longevity or oncology assumptions.

Abstract

Metformin failed in prostate cancer and many others—but exceptions remind us to think with precision about interventions The post Metformin and cancer: active surveillance needed appeared first on Peter Attia MD.

Why this matters

Attia argues that metformin has failed in prostate cancer and many other cancers, and that rare exceptions require precision and active surveillance rather than blanket longevity or oncology assumptions.

Source

Link

Briefing card

Metformin and cancer: active surveillance needed
Stage: expert media · rss · 04-jul-2026

Attia argues that metformin has failed in prostate cancer and many other cancers, and that rare exceptions require precision and active surveillance rather than blanket longevity or oncology assumptions.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://peterattiamd.com/metformin-and-cancer/

build build 880 · 2bcef25 · 2026-11-18